Literature DB >> 6518769

Designs for group sequential tests.

T R Fleming, D P Harrington, P C O'Brien.   

Abstract

Several authors have proposed group sequential procedures to satisfy the ethical need in clinical trials for interim analyses. We propose here an alternative procedure that offers a good opportunity for early termination when initial results are extreme, while essentially maintaining the power provided by the procedure that applies when the corresponding test statistic is computed only at the predetermined time of final analysis. The new design is also sufficiently flexible to readily allow one to increase the maximum number of analyses for certain reasons such as unexpectedly slow accrual into the study, although not for reasons arising from consideration of outcomes observed at interim analysis.

Mesh:

Year:  1984        PMID: 6518769     DOI: 10.1016/s0197-2456(84)80014-8

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  50 in total

Review 1.  [Monitoring of clinical trials. Methodology, interim analyses, and end results].

Authors:  M Pritsch; K Unnebrink
Journal:  Med Klin (Munich)       Date:  1999-12-15

2.  When to stop a clinical trial.

Authors:  S J Pocock
Journal:  BMJ       Date:  1992-07-25

3.  Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials.

Authors:  George Wells; Ratika Parkash; Jeffrey S Healey; Mario Talajic; J Malcolm Arnold; Shannon Sullivan; Joan Peterson; Elizabeth Yetisir; Patricia Theoret-Patrick; Marilynn Luce; Anthony S L Tang
Journal:  CMAJ       Date:  2011-01-31       Impact factor: 8.262

4.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

Review 5.  [Randomized controlled trials terminated prematurely: beneficial therapy effects].

Authors:  L A Kluth; M Rink; S A Ahyai; M Fisch; S F Shariat; P Dahm
Journal:  Urologe A       Date:  2013-08       Impact factor: 0.639

6.  Statistics for surgeons - understanding survival analysis.

Authors:  Girdhar Gopal Agarwal
Journal:  Indian J Surg Oncol       Date:  2012-06-06

7.  The Long-Term Oxygen Treatment Trial for Chronic Obstructive Pulmonary Disease: Rationale, Design, and Lessons Learned.

Authors:  Roger D Yusen; Gerard J Criner; Alice L Sternberg; David H Au; Anne L Fuhlbrigge; Richard K Albert; Richard Casaburi; James K Stoller; Kathleen F Harrington; J Allen D Cooper; Philip Diaz; Steven Gay; Richard Kanner; Neil MacIntyre; Fernando J Martinez; Steven Piantadosi; Frank Sciurba; David Shade; Thomas Stibolt; James Tonascia; Robert Wise; William C Bailey
Journal:  Ann Am Thorac Soc       Date:  2018-01

8.  Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

Authors:  Naga P Chalasani; Arun J Sanyal; Kris V Kowdley; Patricia R Robuck; Jay Hoofnagle; David E Kleiner; Aynur Unalp; James Tonascia
Journal:  Contemp Clin Trials       Date:  2008-09-10       Impact factor: 2.226

9.  Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Kathy S Albain; William E Barlow; Peter M Ravdin; William B Farrar; Gary V Burton; Steven J Ketchel; Charles D Cobau; Ellis G Levine; James N Ingle; Kathleen I Pritchard; Allen S Lichter; Daniel J Schneider; Martin D Abeloff; I Craig Henderson; Hyman B Muss; Stephanie J Green; Danika Lew; Robert B Livingston; Silvana Martino; C Kent Osborne
Journal:  Lancet       Date:  2009-12-10       Impact factor: 79.321

10.  Protocol for a randomized controlled trial on risk adapted damage control orthopedic surgery of femur shaft fractures in multiple trauma patients.

Authors:  Dieter Rixen; Eva Steinhausen; Stefan Sauerland; Rolf Lefering; Matthias Meier; Marc G Maegele; Bertil Bouillon; Edmund A M Neugebauer
Journal:  Trials       Date:  2009-08-19       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.